Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEROID: Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants
NCT07168148Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2025
- Primary completion
- Mar 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of triamcinolone and oxymetazoline in chronic rhinitis and nasal obstruction, sponsored by Washington University School of Medicine. Primary endpoint: Responder rate at 8 weeks. Started Nov 2025; status: terminated.
02
Drugs
triamcinoloneoxymetazoline
03
Conditions
chronic rhinitisnasal obstruction
Beyond the preview
Go deeper on NCT07168148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07168148.